Algorae Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Algorae Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Algorae Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Algorae Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Algorae Pharmaceuticals Ltd (Algorae Pharmaceuticals), is a biotechnology company that discovery, development and commercialization of novel therapeutics for the treatment of debilitating conditions such as Parkinson’s disease, cardiovascular disease, and Alzheimer’s disease. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. Its pipeline products include, NTCELL an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. It is in Phase IIb clinical trials for the treatment of Parkinson's disease. It is also investigating AI-116 for the treatment of dementia and AI-168 for cardiovascular diseases. The company has partnerships collaborations with universities and pharmaceutical companies for development of its product candidates. Algorae Pharmaceuticals is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
Level 23, Rialto South Tower,, 525 Collins Street, Melbourne, Victoria, 3000
Website
www.algoraepharma.com
Telephone
61 3 00288664
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1AI (ASX)
Revenue (2024)
$93,000
12.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
61.7%
(2024 vs 2023)
Market Cap*
$13.0M
Net Profit Margin (2024)
XYZ
66.0%
(2024 vs 2023)
* As of and is in US$
Algorae Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| NTCELL |
| AI-168 |
| AI-116 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company signed a binding term sheet with Cadila Pharmaceuticals Limited to introduce two generic medicines in the Australian and New Zealand markets. |
| 2025 | Contracts/Agreements | In May, the company entered into a partnership with Peter MacCallum Cancer Center for AI driven drug synergy screening. |
| 2024 | New Products/Services | In September, the company announced the launch of its proprietary artificial intelligence platform, AlgoraeOS. |
Competitor Comparison
| Key Parameters | Algorae Pharmaceuticals Ltd | Mesoblast Ltd | Entropy Neurodynamics Ltd | Accelagen Pty Ltd | Biosensis Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | Australia | Australia |
| City | Melbourne | Melbourne | Melbourne | Hawthorn East | Thebarton |
| State/Province | Victoria | Victoria | Victoria | Victoria | South Australia |
| No. of Employees | - | 81 | - | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Hainsworth | Chairman | Executive Board | 2022 | - |
| David Gulland | Chief Operating Officer; Director | Executive Board | 2026 | - |
| James A. Mckenna | Chief Scientific Officer | Senior Management | 2023 | - |
| Vishal Shah | Chief Commercial Officer | Senior Management | 2025 | - |
| Waleed Elsayed | Head - Sales | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer